What drove Quest Diagnostics' earnings growth in 2004?

Net income rose to $499M from $437M, driven by revenue growth of 8.2% and efficiency gains from Six Sigma and standardization initiatives. Cost of services fell to 58.3% of revenue from 58.4%, and SG&A fell to 23.9% from 24.6%, partly due to lower bad debt (4.4% of revenue versus 4.8%). Partial offsets included $13.2M of second-quarter charges, including a $10.3M pension acceleration tied to the CEO transition.

How much cash did the company return to shareholders, and what does it signal?

In 2004 Quest bought back about 8.3M shares for $735M, including a $254M purchase from GlaxoSmithKline, and paid $61M in dividends. The January 2005 authorization expansion to $512M and the dividend increase to $0.18 suggest management is comfortable with its cash generation, though the buybacks were funded partly with borrowings and reduced cash to $73M.

What are the main regulatory risks to investors?

Medicare and Medicaid fee schedules are capped by law, and the CMS and OIG are pursuing changes that could reduce payments, including a proposed exclusion rule tied to 'usual charges' and possible competitive bidding. Potential reinstatement of Medicare co-payments is another risk. A Florida Medicaid competitive bid was withdrawn in February 2005, but similar efforts could return. Qui tam lawsuits and a federal parathyroid hormone testing investigation also carry potential material liability.

How concentrated is the customer base?

Concentration is low. No single customer accounted for more than 6% of 2004 net revenue, and only two customers exceeded 5%. Healthcare insurers represent about half of revenue, and about 13% comes from hospitals. Management believes losing any single customer would not have a material adverse effect.

What is the balance sheet and goodwill exposure?

Total assets were $4.2B, with goodwill of $2.5B, or about 60% of assets, and stockholders' equity of $2.29B. Management tested goodwill for impairment at year-end 2004 and found none. Because goodwill is large relative to equity, a sustained decline in fair value could trigger a significant impairment charge.

DGX 10-K FY2004 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 10, 2005. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) closed 2004 with net revenues of $5.13 billion^a, up 8.2% year over year, and net income of $499 million, up about 14% from $437 million in 2003.

Diluted EPS was $4.69^b versus $4.04. Pro forma revenue growth was 6.7%, and pro forma testing volume rose 3.2%. Operating margin improved to 17.4% from 16.8%, driven by Six Sigma efficiencies, higher average revenue per requisition (up 2.6%), and a shift toward gene-based and esoteric testing, which the company says generated about $600 million in revenue and is growing over 10% annually.

Operating cash flow rose to $799 million^c, and days sales outstanding improved to 47 days. Capital was returned to shareholders aggressively. Quest repurchased about 8.3 million shares for $735 million in 2004, including a $254 million buyback from GlaxoSmithKline, and it initiated its first quarterly dividend in late 2003 (raised to $0.18 per quarter in January 2005).

Share repurchase authorization was expanded by $350 million in January 2005 to $512 million^d. Leverage was reduced: long-term debt fell to $724 million from $1.03 billion, largely because the 1.75% contingent convertible debentures were called and converted in January 2005. Key risks remain substantial.

Medicare and Medicaid made up about 17% of revenue, reimbursement faces ongoing pressure from fee-schedule limits, proposed OIG 'usual charges' rules, and possible competitive bidding, and the company is cooperating with a federal subpoena on parathyroid hormone testing and facing qui tam suits. Healthcare insurers account for roughly half of revenue, and their capitation and non-exclusive contracting trends are pressuring pricing.

Note that the Florida Medicaid competitive bid was withdrawn in February 2005. Goodwill of $2.5 billion, about 60% of total assets, is also a sensitive exposure if performance weakens.

02—Key points

Key Highlights

Revenue of $5.13B in 2004, up 8.2% (6.7% pro forma), with testing volume up 5.0% reported and 3.2% pro forma
Net income of $499M (+14%) and diluted EPS of $4.69 versus $4.04, with operating margin expanding to 17.4% from 16.8%
Gene-based testing generated about $600M in revenue, growing over 10% per year, and the company claims the largest U.S. gene-based testing business
Operating cash flow of $799M, up from $663M, and DSO improved to 47 days from 48
Aggressive capital return: $735M in 2004 buybacks (8.3M shares at $88.21 average), first dividend at $0.15 quarterly, raised to $0.18 in January 2005, with buyback authorization expanded to $512M
Long-term debt reduced to $724M from $1.03B, and the 1.75% convertible debentures were redeemed or converted in January 2005
Concentrated regulatory and reimbursement exposure: Medicare/Medicaid ~17% of revenue, pending qui tam suits, and a federal subpoena in the Eastern District of New York

03—Questions

Frequently Asked Questions

What drove Quest Diagnostics' earnings growth in 2004?
Net income rose to $499M from $437M, driven by revenue growth of 8.2% and efficiency gains from Six Sigma and standardization initiatives. Cost of services fell to 58.3% of revenue from 58.4%, and SG&A fell to 23.9% from 24.6%, partly due to lower bad debt (4.4% of revenue versus 4.8%). Partial offsets included $13.2M of second-quarter charges, including a $10.3M pension acceleration tied to the CEO transition.
How much cash did the company return to shareholders, and what does it signal?
In 2004 Quest bought back about 8.3M shares for $735M, including a $254M purchase from GlaxoSmithKline, and paid $61M in dividends. The January 2005 authorization expansion to $512M and the dividend increase to $0.18 suggest management is comfortable with its cash generation, though the buybacks were funded partly with borrowings and reduced cash to $73M.
What are the main regulatory risks to investors?
Medicare and Medicaid fee schedules are capped by law, and the CMS and OIG are pursuing changes that could reduce payments, including a proposed exclusion rule tied to 'usual charges' and possible competitive bidding. Potential reinstatement of Medicare co-payments is another risk. A Florida Medicaid competitive bid was withdrawn in February 2005, but similar efforts could return. Qui tam lawsuits and a federal parathyroid hormone testing investigation also carry potential material liability.
How concentrated is the customer base?
Concentration is low. No single customer accounted for more than 6% of 2004 net revenue, and only two customers exceeded 5%. Healthcare insurers represent about half of revenue, and about 13% comes from hospitals. Management believes losing any single customer would not have a material adverse effect.
What is the balance sheet and goodwill exposure?
Total assets were $4.2B, with goodwill of $2.5B, or about 60% of assets, and stockholders' equity of $2.29B. Management tested goodwill for impairment at year-end 2004 and found none. Because goodwill is large relative to equity, a sustained decline in fair value could trigger a significant impairment charge.

04—Continue

← View all 10-K filings